Pharmaceutical and chemical company, PT Merck Tbk recorded a decrease in net income in 2012. The German issuers, incised profit of Rp 108 billion, down 53.24% from the previous period which amounted to Rp 231.16 billion.
Director of Finance Bambang Nurcahyo explain, the decline in 2012 net profit, due in 2011, the company is selling assets. This has an impact on revenues soaring Merck in 2011, while in 2012, there is no asset sales.
“The decline in performace 2012, causes the 2011 to sell property assets and Kemang BSD net profit of Rp 70 billion. Assets sold in 2011,” said Bambang at Public Expose Merck headquarters in Pasar Rebo, East Jakarta, Wednesday (20/03/2013).
In 2012, Merck’s sales reached Rp 930 billion, up 1.18% from the 2012 period amounted to Rp 919 billion. This sale, supported by three business units namely Chemicals Rp 359 billion, Merck Serono worth Rp 405 billion and Rp Consumer Healthcare 166 billion.
Merck also will perform a dividend of Rp 75 billion to shareholders. However, Bambang reluctant to mention the target profit, revenue and business plans and capital expenditures in 2013.